Edwards Lifesciences Corporation, the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that Steven R. Loranger has been appointed to its board of directors. Loranger was most recently chief executive officer and president of leading global water technology company Xylem Inc., following his service as chairman, president and chief executive officer of ITT Corporation for seven years.
Prior to joining ITT, Loranger served as executive vice president and chief operating officer of Textron, Inc., and held executive positions at Honeywell International Inc. and its predecessor company, AlliedSignal, Inc.
“We are excited to welcome Steve to our board of directors, which will benefit from his decades of experience leading large, innovation-focused corporations,” said Michael A. Mussallem, Edwards’ chairman and CEO. “We look forward to his insights and global experience gained from service in a variety of highly regulated, high-tech industries with significant focus on quality.”
Currently, Loranger serves on the boards of directors of Xylem, Inc., the Smithsonian National Air and Space Museum and the Congressional Medal of Honor Foundation. He also served on the board of FedEx Corporation from 2006 to 2014.
A former U.S. Navy lieutenant, Loranger holds bachelor’s and master’s degrees from the University of Colorado.
Source: Edwards Lifesciences
Antibiotic resistance remains one of the biggest public health challenges. New drugs are still needed to tackle tough-to-treat bacteria. But finding new therapeutics to kill off pathogenic bacteria has been difficult.
Viral vectors are engineered viruses used to deliver gene therapies, gene-modified cell therapies and certain vaccines. And their shortage is already upon us, thanks to manufacturing approaches that simply haven’t kept pace with the advance of cell and gene therapies.
Beigene, a fast-growing drugmaker based in Cambridge, Massachusetts and Beijing, will partner with Shoreline Biosciences to develop cell therapies for cancer, expanding its research beyond the small molecule and antibody drugs.
